<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Project1</title>
    <link
      href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css"
      rel="stylesheet"
      integrity="sha384-T3c6CoIi6uLrA9TneNEoa7RxnatzjcDSCmG1MXxSR1GAsXEV/Dwwykc2MPK8M2HN"
      crossorigin="anonymous"
    />
  </head>
  <style>
    .report {
        width: 60%;
        margin-bottom: 10em;
    }
    img {
        display: block;
        margin-left: auto;
        margin-right: auto;
        margin-top: 2rem;
    }
    .bg-custom {
      background-image: url("your-background-image-url.jpg");
      background-size: cover;
      color: rgb(190, 143, 143);
    }
    .profile-pic {
      max-width: 200px;
      margin: 0 auto;
      margin-top: 3em;
    }
    .custom-border {
      border-width: 5px !important; /* Adjust the border width as needed */
      border-color: rgb(
        143,
        123,
        123
      ) !important; /* Optional: change the border color */
      border-radius: 20px;
    }
    .dropdown-menu a {
      color: rgb(136, 70, 106);
    }
  </style>
  <nav class="navbar navbar-expand-sm navbar-dark  fixed-top" style="background-color: rgb(224, 143, 188);">
    <div class="container-fluid">
      <!-- <a class="navbar-brand" href="javascript:void(0)">Home</a>
      <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#mynavbar">
        <span class="navbar-toggler-icon"></span>
      </button> -->
      <div class="collapse navbar-collapse" id="mynavbar">
        <ul class="navbar-nav me-auto">
          <li class="nav-item" style="margin-right: 10px;">
            <a class="nav-link" href="./index.html" style = "color: white;">Home</a>
          </li>
          <li class="nav-item dropdown">
            <a
              class="nav-link dropdown-toggle"
              href="#"
              role="button"
              data-bs-toggle="dropdown" style = "color: white;"
              >Project</a>
            <ul class="dropdown-menu">
              <li>
                <a class="dropdown-item" href="./project1.html"
                  >CFA Research Challenge : Stock Price Prediction</a
                >
              </li>
              <li>
                <a class="dropdown-item" href="./project2.html"
                  >Portfolio Analysis (Python, Pandas)</a
                >
              </li>
              <li>
                <a class="dropdown-item" href="./project3.html"
                  >House price prediction (MLP)</a
                >
              </li>
              <li>
                <a class="dropdown-item" href="./project4.html"
                  >Image Classification (CNN)</a
                >
              </li>
              <li>
                <a class="dropdown-item" href="./project5.html"
                  >Collaborative Filtering (Deep Learning)</a
                >
              </li>
              <li>
                <a class="dropdown-item" href="./project6.html"
                  >Ruin Probability Prediction (R)</a
                >
              </li>
              <li>
                <a class="dropdown-item" href="./project7.html"
                  >Health status prediction (R)</a
                >
              </li>
                            <li>
                <a class="dropdown-item" href="./project8.html"
                  >Data Visualization (Tableau)</a
                >
              </li> 
            </ul>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="./resume.html" style = "color: white;">Resume</a>
          </li>
        </ul>
        <!-- <form class="d-flex">
          <input class="form-control me-2" type="text" placeholder="Search" />
          <button class="btn btn-primary" type="button" style = "background-color: rgb(125, 145, 211); border: none;">Search</button>
        </form> -->
      </div>
    </div>
  </nav>
    <div style = "margin-bottom: 5em;"></div>
    <div class = "container report">
        <p style="margin: 0pt; orphans: 0; text-align: center; widows: 0">
          <img
            src="./project1_img/Picture1.png"
            width="554"
            height="113"
            alt=""
            style="
              -aw-left-pos: 0.3pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 9.4pt;
              -aw-wrap-type: topbottom;
            "
          /><br />
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: center; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 16pt;
              font-weight: bold;
            "
            >C</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 16pt;
              font-weight: bold;
            "
            >FA Institute Research Challenge</span
          >
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: center; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 16pt;
              font-weight: bold;
            "
            >Stock Price Prediction for </span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 16pt;
              font-weight: bold;
            "
            >BioTechnology</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 16pt;
              font-weight: bold;
            "
          >
            Co., Ltd(688363.SH)</span
          >
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span style="font-family: 等线; font-size: 10.5pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >INVESTMENT SUMMARY</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >Since going public on the Science and Technology Innovation Board of
            the Shanghai Stock Exchange in 2019, recent years have witnessed a
            rapid progress of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            business performances together with its stock price. As the world’s
            leading enterprise in the hyaluronic acid (HA) production currently, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            tends to be lucrative and promising for investors.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >We issue a buy recommendation on </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            with an expecting target price 203.99 CNY on 2022-2-28. To be
            specific, if an investor who takes our recommendation buys </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            at current price 161.25 CNY (2021-11- 30 close) and sells it about
            three months later, a 26.51% profit return is expected to achieve
            under the assumption that the market have exploited most of its
            intrinsic value. The investment logic is concluded based on the
            following key ideas:
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >1) Integrated industrial chain provides with robust fundamental.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >2) Sustainable financial growth and low financial risk indicate a
            potential future development</span
          ><span style="font-family: Calibri; font-size: 12pt">. </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >3) A valuation result at 203.99 CNY based on </span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >ReOI</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
          >
            model indicates that </span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Bloomage</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
          >
          </span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >BioTech</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
          >
            is currently underpriced.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >4) The convincing validation towards the valuation has been conducted
            through sensitivity analysis and Monte Carlo simulation.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: 宋体; font-size: 12pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >BUSINESS DESCRIPTION</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Business Segments</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The revenue structure of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is composed of four segments: functional skin care products (51.12%),
            HA raw materials (26.70%), medical terminal products (21.88%) and
            other products (0.27%). Compared to last year’s revenue structure, the
            revenue from functional skin care products increased by 112.19% and
            achieved CNY1.346B. This explosive growth resulted from the company's
            aggressive online </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >marketing strategy. Due to COVID-19, revenue from raw materials
            decreased by 7.55%. The revenue of medical </span
          ><img
            src="./project1_img/Picture2.png"
            width="240"
            height="270"
            alt=""
            style="
              -aw-left-pos: 129.76pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 40.4pt;
              -aw-wrap-type: topbottom;
            "
          /><br /><span style="font-family: Calibri; font-size: 12pt"
            >terminal products increased by 17.79%, showing a potential growth
            trend.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Industrial Chain Management</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The industry chain of medical cosmetology mainly includes three
            links: the upstream is raw material and equipment suppliers, the
            midstream is service agencies, and the downstream is customer
            acquisition platforms. As the world's largest supplier of HA raw
            materials, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            builds an industrial chain that contains research and development, </span
          ><span style="font-family: Calibri; font-size: 12pt">production</span
          ><span style="font-family: Calibri; font-size: 12pt">
            and sales of HA products.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: 宋体; font-size: 12pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >INDUSTRY OVERVIEW</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Raw material Market</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is the worldwide largest HA production enterprise, whose sales
            accounts for 36%. Other leading enterprises include Focus Chem, </span
          ><span style="font-family: Calibri; font-size: 12pt">Fufeng</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt"> and </span
          ><span style="font-family: Calibri; font-size: 12pt">LookChem</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >, whose market share are 12%, 10% and 8% (Fig.3), respectively.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Terminal Product Market of Medical Cosmetology</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >In China, the market size of medical cosmetology reaches CNY 197.5
            billion with CAGR of 23.38% from 2012 to 2020. The permeability rate
            in China is only 3.6% in 2019, which is greatly less than other
            developed country, such as America and Korea, whose permeability rate
            are 16.6% and 20.5%, respectively (Fig. 4). Data from The New Oxygen
            Data Institute showed that in 2020, the number of medical and beauty
            consumers in China reached 15.2 million, with a year-on- year increase
            of 35.7%. By April 2021, the number of medical beauty users in China
            has reached 18.073 million, and medical beauty consumption continues
            to be hot. Therefore, we expect that the market size will increase to
            CNY 311.5 billion in 2023 (Fig. 5). Because the popularity and price
            of domestic HA are relatively low, Chinese HA medical cosmetology
            market is dominated by well-known foreign brand. In 2019, domestic HA
            product only accounted for 28% of the market share (Fig.6).
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >High Entering Technology Barriers</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >In raw material market, for pharmaceutical level HA raw material,
            there is a high requirement for the purity index of endotoxin,
            protein, nucleic acid and colony. For the terminal product, especially
            the injection medical cosmetology products, there </span
          ><span style="font-family: Calibri; font-size: 12pt">are have</span
          ><span style="font-family: Calibri; font-size: 12pt">
            high research and development costs and technical threshold. Take
            terminal production leading enterprises as an example, the research
            &amp; development personnel of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">, </span
          ><span style="font-family: Calibri; font-size: 12pt">Haohai</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            and IMEIK take up 16.8%, 19.7% and 22.9%, respectively. And they have
            also invested 0.14, 1.26 and 0.59 million, respectively, into research
            &amp; development.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Strong supervision benefits the development of leading
            enterprises</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >Starting from 2002, China has begun to intensify supervision on
            medical cosmetology industry and successively published dozens of
            regulations to </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >standardize for medical cosmetology equipment and drugs. For
            pharmaceutical raw material manufacturers, to obtain the production
            approval, they need to acquire different qualifications and the
            overall process will take 2 to 5 years. </span
          ><img
            src="./project1_img/Picture3.png"
            width="500"
            height="400"
            alt=""
            style="
              -aw-left-pos: 45.77pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 53.72pt;
              -aw-wrap-type: topbottom;
            "
          /><span style="font-family: Calibri; font-size: 12pt"
            >
          </span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span style="font-family: 等线; font-size: 10.5pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span style="font-family: 等线; font-size: 10.5pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >COMPETITOR POSITIONING</span
          >
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span style="font-family: 等线; font-size: 10.5pt">&#xa0;</span>
        </p>
        <span style="font-family: Calibri; font-size: 12pt"
            >Based on the similar focus on HA production and the high net profits,
            IMEIK and </span
          ><span style="font-family: Calibri; font-size: 12pt">Haohai</span
          ><span style="font-family: Calibri; font-size: 12pt">
            Biological Technology are considered as the main competitors of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            to conduct the following analyses. Compared with other competitors, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is very profitable with extremely high operating income and relatively
            steady rate of growth. Facing the impact COVID-19, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            chooses to stimulate the development of C-end business, which helps it
            maintain a high gross profit in the fierce market competition. At the
            same time, IMEIK still focused on the development of B-end products
            while </span
          ><span style="font-family: Calibri; font-size: 12pt">Haohai</span
          ><span style="font-family: Calibri; font-size: 12pt">
            was seriously affected by the epidemic (Fig. 7). </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The high profitability and stability of it also benefit from its
            stronger research and development capabilities and expansion of the
            functional food sector.</span
          >
          <p style="background-color: #ffffff; margin: 5pt 0pt">
            <img
              src="./project1_img/Picture4.png"
              width="231"
              height="186"
              alt=""
              style="
                -aw-left-pos: 109.5pt;
                -aw-rel-hpos: column;
                -aw-rel-vpos: paragraph;
                -aw-top-pos: 149.91pt;
                -aw-wrap-type: topbottom;
              "
            /><br />
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: 宋体; font-size: 12pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >FINANCIAL ANALYSIS</span
          >
        </p>

        <p style="background-color: #ffffff; margin: 7pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Sustainable revenue growth driven by reasonable layout of three
            business lines</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has an industry leading position in HA manufacturing, so until 2019,
            raw material manufacturing and sales are the main business, which
            accounts for 40.35% of total sales (Fig. 8) In 2020, functional skin
            care products surpassed raw material to be </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            main business segment at a revenue contribution rate of 51.12% (Fig.
            8). This line generated 1.35 billion yuan of revenue with an extremely
            high CAGR 114%, indicating the functional skin care products line is
            enriching the single raw material sales line and becoming a new sales
            growth point. Although the proportion of raw material business line
            declines drastically and medical terminal products line maintains a
            low business percentage of 24%, they keep a stable growth of revenue
            with CAGR 11.3%, 31.8% respectively. At the same time, recent
            increased supervision of internet, education and medical beauty
            industries led by government policy may slow down </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            revenue growth level. However, according to the data above, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has turned to the C-end as a new growing point to better adapt to the
            industry standardization trend. Thus, we expect </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            revenue to grow 21% faster than the industry average growth rate in
            the following three years, which equals to 23.38%. To sum up, we see a
            great overall development power.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 7pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >High gross margin attributed to advanced technology</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The gross margin of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            maintains at a fairly high level, with an average of 78.76% in the
            past five years (Fig. 9) It is attributed to its advanced technology
            and professional production line in HA manufacture with a low COGS.
            However, its profit is relatively low, but is still competitive to </span
          ><span style="font-family: Calibri; font-size: 12pt">Haohai</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt"> and </span
          ><span style="font-family: Calibri; font-size: 12pt">Imeik</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >. We explore the principal factor. Biopharmaceutical industry is
            technology intensive. Its product development cycle is long and
            R&amp;D investment will be no immediate result. Thus, in some years,
            like 2017 and 2020, the investment expenses didn’t pay back yet, so
            the ROE is lower. It is also worth noting that </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            total R&amp;D investment in 2020 is NCY 141.16 million according to
            its annual report. The company counted all of it as expensed R&amp;D
            and the capitalized R&amp;D is counted 0, which significantly declined
            profit for the year.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Continuous improvement of debt solvency</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The current ratio of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            raised from 2.56 in 2016 to 6.63 in 2020, and the quick ratio from
            2.14 to 4.59. According to the data, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            short-term solvency improved in the past 5 years. The company has a
            low risk of short-term debt repayment crisis. As for long-term
            solvency, we see the Debt-Asset ratio of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            in 2019 decreased significantly because of the substantial increase in
            assets duo to the listing (Fig. 10) However, the ratio picked up in
            2020, larger than that of </span
          ><span style="font-family: Calibri; font-size: 12pt">Haohai</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt"> and </span
          ><span style="font-family: Calibri; font-size: 12pt">Imeik</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >. It may be caused by the industry regulatory policy and increased
            R&amp;D investment in order to conform to the market such as HA </span
          ><span style="font-family: Calibri; font-size: 12pt">food, but</span
          ><span style="font-family: Calibri; font-size: 12pt">
            compared with the industry average level of Debt-Asset ratio around
            60%, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is still at a fairly low level.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Insufficient R&amp;D investment may block future transactions in
            international competition</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has been committed to create a </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTechnology</span
          ><span style="font-family: Calibri; font-size: 12pt">
            company driven by R&amp;D since its foundation. It constantly
            increased R&amp;D investment in the past three years (Fig. 11). By
            2020, it has employed 377 researchers in total and patented 289
            inventions. In the domestic market, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has been in an industry leading position. However, for foreign
            biopharmaceutical enterprises of the same scale, the percentage of
            R&amp;D investment to operating revenue is about 8%, which is much
            higher than </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            proportion.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <img
            src="./project1_img/Picture5.png"
            width="600"
            height="450"
            alt=""
            style="
              -aw-left-pos: 26.83pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 3.15pt;
              -aw-wrap-type: topbottom;
            "
          /><br />
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >VALUATION</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >According to the result of our valuation model, the BUY
            recommendation is put forward on </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            with a target price of 203.99 CNY on Feb. 28</span
          ><span style="font-family: Calibri; font-size: 7pt; vertical-align: 3pt"
            >th</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >, 2021. Compared with the closing price on Nov. 30</span
          ><span style="font-family: Calibri; font-size: 7pt; vertical-align: 3pt"
            >th</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >, 2021, which is 161.25 CNY, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has a 26.51% upside of price in the following 3 months. Due to our
            relatively conservative assumptions, the valuated price is lower than
            the one which is more generally accepted by the institutions. We still
            propose a BUY recommendation based on its huge growth space. We use </span
          ><span style="font-family: Calibri; font-size: 12pt">ReOI</span
          ><span style="font-family: Calibri; font-size: 12pt"> model (</span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is expected to generate stable residual earnings in the future) to
            value </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            with auxiliary P/E method and quantitative analysis verifying our
            valuation (Fig. 12).
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >I. Key Assumptions: the adjusted discount rate.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >The discount rate is calculated by WACC model formulated as
            below:</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt; text-align: center">
          <span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Discount Rate = WACC = D/V * Rd * (1 - T) + E/V * Re</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >The Equity-to-Debt ratio is calculated based on the Balance Sheet on
            Dec 31</span
          ><span style="font-family: Calibri; font-size: 7pt; vertical-align: 3pt"
            >st</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >, 2020. The cost of debt is estimated based on the yield to maturity
            on Nov. 30</span
          ><span style="font-family: Calibri; font-size: 7pt; vertical-align: 3pt"
            >th</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >, 2021, of a listed long-term bond of a comparable corporation, </span
          ><span style="font-family: Calibri; font-size: 12pt">Lancy</span
          ><span style="font-family: Calibri; font-size: 12pt"> (</span
          ><span style="font-family: Calibri; font-size: 12pt">Lancy</span
          ><span style="font-family: Calibri; font-size: 12pt"> and </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            are in the same industry with similar business model). The cost of
            equity is estimated by CAPM which takes the risk premium into account
            and is in accordance with the investors’ consideration of risk
            compensation: (a) The market return is calculated by the CAGR of CSI
            300 in the past two years which can reflect market return. (b) Beta is
            calculated based on the returns of CSI 300 and </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            in the past two years. (c) The risk-free rate is represented by the
            weighted average 1-year treasury bond interest rate in 2021. The tax </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >rate is calculated using the average tax rate in the past 5 report
            periods. Eventually, we can get a discount rate 14.11% (Fig. 14).
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >II. Estimating the Operating Income in the next 5 years
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >(a) Default assumptions by institutions.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >The industry net profit margin can be regarded as the benchmark of
            the corporation’s net profit margin indicator. The Bio-pharmaceutical
            industry has a net profit margin of 9.04% in 2019 (Since the
            production of Bio- pharmaceutical industry in 2020 was seriously
            affected by the epidemic, where the financial data suffered from a
            large deviation). Besides, the corporation’s annual net profit growth
            rate is publicly accepted to approach Bio-pharmaceutical industry’s
            compound annual net profit growth rate.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >(b) Adjustments for existing assumptions.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt">Because </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is one of the leading enterprises of Bio- pharmaceutical industry, it
            far outperforms the industry average. In addition, based on our
            profound insights from the industry, competitors, and the corporation
            itself, we make some adjustment to the previous corporation’s growth
            assumptions.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >The future operating income is mainly based on </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            future business plan and current market pattern. The compound annual
            growth rate of revenue from 2018 to 2020 is 44.37%. Because of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt">
            comparative advantaged among its main competitors, including high
            market share of the global HA market and abundant investment in
            R&amp;D, we assume </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            will maintain a stable revenue growth rate at 44.37% in the following
            3 years. The revenue for the first half year of 2021 is
            1,936,614,650.94 which is relatively close to the estimation and can
            be considered as a verification of the assumption. The average net
            profit margin in the past three years is 23.70%. Combined with the
            industry average, we have made a compromise. Based on the advantages
            (e.g., high entry barriers and High </span
          ><span style="font-family: Calibri; font-size: 12pt">R</span
          ><span style="font-family: Calibri; font-size: 12pt">&amp;</span
          ><span style="font-family: Calibri; font-size: 12pt">D</span
          ><span style="font-family: Calibri; font-size: 12pt">
            capability and the disadvantages (e.g., High market saturation), we
            assume the net profit margin will maintain at 19.37% in the following
            5 years.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >The compound annual net profit growth rate of the Bio-pharmaceutical
            industry in the past 10 years is 10.46%. The long-term development
            trend of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            should have been bound to converge with the development trend of the
            bio-pharmaceutical industry in the long run. But </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is also an untypical medical beauty company High-tech content. The
            entry barrier of medical beauty industry is relatively low. Thus, the
            current situation of medical beauty industry is that head effect is
            not greatly significant with high diversification of numerous
            small-scale medical beauty companies. Medical beauty industry also has
            a high market saturation rate, so the traditional 2C business has
            little room for growth. Benefitting from the national policy of
            medical beauty industry rectification and reform released several
            months ago, the phenomenon of non-standardized industry will be
            mitigated, and the development of leading enterprises will be
            supported. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is expected to gradually increase its market share in the medical
            beauty industry. In addition, according to the </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            current business pattern, the 2B business has begun to take shape and
            had a good development trend. It has huge growth potential in the
            future to break the development </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >bottleneck of the traditional medical beauty industry. Therefore, we
            still assume </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s net profit will maintain a stable growth rate at 10.46% after 3
            years.</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><img
            src="./project1_img/Picture6.png"
            width="600"
            height="380"
            alt=""
            style="
              -aw-left-pos: 0.3pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 38.5pt;
              -aw-wrap-type: topbottom;
            "
          /><br /><span style="font-family: Calibri; font-size: 12pt"
            >
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt">&#xa0;</span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >III. </span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >ReOI</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
          >
            Results.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt"
            >Based on the formulas:
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt; text-align: center">
          <span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >NOA</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t </span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >= NOA</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t-1 </span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >* (1 + RNOA) = NOA</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t-1 </span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >* (1 + OI</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >/ NOA</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t-1</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >)</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt; text-align: center">
          <span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >ReOI</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t </span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >= OI</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t-1 </span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >– (ρ – 1) * NOA</span
          ><span
            style="
              color: #006dbf;
              font-family: Calibri;
              font-size: 7pt;
              font-weight: bold;
              vertical-align: -2pt;
            "
            >t-1</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <img
            src="./project1_img/Picture7.png"
            width="300"
            height="250"
            alt=""
            style="
              -aw-left-pos: 123.46pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 84.48pt;
              -aw-wrap-type: topbottom;
            "
          /><br /><span style="font-family: Calibri; font-size: 12pt"
            >Using the updated assumptions above, we apply the </span
          ><span style="font-family: Calibri; font-size: 12pt">ReOI</span
          ><span style="font-family: Calibri; font-size: 12pt">
            model to calculate the target price, which is equal to 230.42 CNY
            (Fig. 14). This target price suggests that by the end of February of
            2022, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            will earn a 26.51% return if it is relatively </span
          ><span style="font-family: Calibri; font-size: 12pt">fairly priced</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >. This target price is lower than the generally accepted price 239.30
            CNY by institutions, however, still indicating a high profit margin
            with 3 months. Therefore, we put forward a BUY recommendation.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt">&#xa0;</span>
        </p>
        <p style="margin: 0pt; orphans: 0; text-align: justify; widows: 0">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >VERIFICATION OF THE TARGET PRICE</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >I. Robustness of </span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >ReOI</span
          ><span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
          >
            Model.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt">T</span
          ><span style="font-family: Calibri; font-size: 12pt">he </span
          ><span style="font-family: Calibri; font-size: 12pt">ReOI</span
          ><span style="font-family: Calibri; font-size: 12pt">
            model heavily relies on the estimated discount rate and net profit
            growth rate. Therefore, we think that it is necessary to carry out a
            sensitivity analysis on these two variables. Based on our relatively
            solid assumptions, the adjustment range of these two variables is
            slight in the sensitivity analysis. In the most conservative scenario,
            we still expect a 17.08% upside of price in the following 3 months
            while 37.56% for the most optimistic scenario.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >II. Monte Carlo Simulation.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <img
            src="./project1_img/Picture8.png"
            width="500"
            height="400"
            alt=""
            style="
              -aw-left-pos: 65.98pt;
              -aw-rel-hpos: column;
              -aw-rel-vpos: paragraph;
              -aw-top-pos: 116.01pt;
              -aw-wrap-type: topbottom;
            "
          /><br /><span style="font-family: Calibri; font-size: 12pt"
            >Based on historical price of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            in the past two years, we apply Monte Carlo simulation to simulate
            stock price movement in the end of 2021. Therefore, we can get some
            insights of the intrinsic value of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            in the perspective of statistics. From the simulation, the average
            price of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is 236.80 after 3 months. Besides, we find that there is a probability
            of 64.3% to obtain a price above the current price and a probability
            of 49.78% to obtain a price above the target price, which effectively
            justifies our estimation. Therefore, the robustness of </span
          ><span style="font-family: Calibri; font-size: 12pt">ReOI</span
          ><span style="font-family: Calibri; font-size: 12pt">
            model has been verified (Fig. 15 &amp; 16).
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="font-family: Calibri; font-size: 12pt">&#xa0;</span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >INVESTMENT RISK</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Market risk</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Potential Decrease in Demand: </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >Although it is now in the post-epidemic period, as close to 65% of
            the company’s HA products are sold abroad, blockades and measures to
            respond to the epidemic in some regions will still cause product sales
            to fall (0~20%). However, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            entire industrial chain will play a strong positive role in avoiding
            some market fluctuation risks. Even if </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            meets some reduced demand during the economic recession, we expect
            that </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt">
            Biotech will be able to ride out COVID-19 pandemic with more than CNY
            3,800.87 million in revenue on its balance sheet.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Financial risk</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Exchange Rate Risk: </span
          ><span style="font-family: Calibri; font-size: 12pt">43% of </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            revenue in fiscal 2020 was from countries outside China, but no
            country outside of China generated more than 8% of Microsoft’s
            revenue. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            is exposed to volatility in exchange rate, but diversification, option
            and forward contracts can hedge a portion of forecasted international
            revenue. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            estimates that currency variation will reduce 2% of revenue and
            increase 1% of selling cost and operational expenses.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Interest Rate Risk: </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            long-term debt increased from CNY 423.5 million in 2016 to CNY 698.8
            million in fiscal 2020. In the short term, People's Bank of China has
            cut long-term interest rates to prop up the China economy, so </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            faces a lower cost of debt. But interest fluctuation may impact </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            consolidated financial statements in the long term.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Operational risk</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >New Product Line Risk: </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            may make investments in new product line that may not achieve expected
            returns. Starting from January 21, 2021, the company has developed
            HA-related products, including oral liquids, soft sweets, and
            compressed candies. In 2016, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            and Shandong College of Pharmacy released the paper "Study on the
            Improvement Effect of Oral Hyaluronic Acid on Skin Moisture and
            Antioxidant Effect in the Body". The paper shows that in a controlled
            experiment, the experimenter took 120 mg of hyaluronic acid every day
            for 45 days, and his skin moisture increased from 8.7% to about 9.6%.
            Nevertheless, the conclusions of related experiments are still
            controversial.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Corporate Governance Risk: </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >On December 25, 2020, the company's director, deputy general manager
            and secretary of the board of directors Rui Jiang stepped down from </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            Board of Directors. With Rui’s departure, the power struggle in the
            Board may occur and raise agency costs.</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Renewal of Business Qualification: </span
          ><span style="font-family: Calibri; font-size: 12pt">In 2021, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            will have 14 certification certificates and other business
            qualifications to expire one after another, and the company has now
            carried out corresponding renewal work. According to some domestic
            laws and regulations in China, pharmaceutical device manufacturers
            need to obtain a series of business qualifications for production,
            registration, sales, and export, before the relevant qualifications
            expire. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            needs to apply for certificate renewal in time.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Political Risk
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Governmental Restriction: </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >Government litigation and regulatory activities relating to
            competition rules may limit how </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            designs and market its products.</span
          ><br /><span
            style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >International Restriction</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >: Potential liability under trade protection, anti-corruption, and
            other laws about </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            global operations may bring legal claims, fines, or reputational
            damage.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Industry Risk
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Governmental Restriction</span
          ><span style="color: #1e4c77; font-family: Calibri; font-size: 12pt">
            &amp; </span
          ><span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Intense Competition: </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            must be in pace with the changing environment and invest in
            infrastructure and devices, which may increase operating costs and
            decrease operating margins (Fig. 17).
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
              text-decoration: underline;
            "
            >ESG ANALYSIS</span
          >
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Low carbon operation, energy saving and environmental
            protection</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The company fully implemented "Made in China 2025" and "Green
            Manufacturing Engineering Implementation Guidelines", introduced the
            design and management concepts of green factories, and established a
            green factory management organization. The green factory management
            organization has carried out in-depth research and analysis in many
            aspects such as product development direction, production technology
            and process equipment, starting from the aspects of production
            automation, plant intensification, harmless raw materials, waste
            recycling, and low-carbon energy. The establishment of a green factory
            standard system has effectively reduced the impact of the product's
            entire life cycle on the environment. </span
          ><span style="font-family: Calibri; font-size: 12pt">In order to</span
          ><span style="font-family: Calibri; font-size: 12pt">
            effectively control the various pollutants produced by the company in
            the production and operation process and reduce the impact on the
            environment, the company has invested a total of 8.6 million yuan in
            environmental protection in 2020.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Protection of intangible cultural heritage</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            regards inheriting Chinese culture and protecting "intangible cultural
            heritage" as one of the indispensable social responsibilities of the
            enterprise. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has been excavating and protecting my country’s immaterial intangibles
            that are on the verge of disappearing for 10 consecutive years.
            Cultural heritage is protected and passed on through the "</span
          ><span style="font-family: Calibri; font-size: 12pt">Yunzhong</span
          ><span style="font-family: Calibri; font-size: 12pt">
            Series" activities every year.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Measures for COVID-19</span
          ><span
            style="
              color: #1e4c77;
              font-family: 宋体;
              font-size: 12pt;
              font-weight: bold;
            "
            >：</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >After the outbreak of COVID-19, </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            established an epidemic response leadership group, and fully mobilized
            various resources to immediately organize the production of "</span
          ><span style="font-family: Calibri; font-size: 12pt">Runbaiyan</span
          ><span style="font-family: Calibri; font-size: 12pt">
            Medical Disinfectant Gel" to aid the epidemic area. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt">
            has delivered twelve batches of anti-epidemic and living supplies such
            as </span
          ><span style="font-family: Calibri; font-size: 12pt">Runbaiyan</span
          ><span style="font-family: Calibri; font-size: 12pt">
            medical disposable disinfectant gel to more than 50 anti-epidemic
            first-line hospitals in more than 20 urban areas. And the medical team
            assisting Hubei made targeted donations, and the accumulated donated
            materials exceeded 10 million yuan.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span
            style="
              color: #1e4c77;
              font-family: Calibri;
              font-size: 12pt;
              font-weight: bold;
            "
            >Corporate
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Progressive Framework | </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The purpose of corporate governance framework is to let Board of
            Directors have enough authority and make sure practices are in place,
            enabling them to evaluate business operations and to make decisions
            independently. The directors make every effort to balance the
            interests of directors, management, and shareholders. </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech’s</span
          ><span style="font-family: Calibri; font-size: 12pt">
            framework also establishes the practices include many parts such as
            “board meetings and involvement of senior management”, “CEO
            performance evaluation”, and “senior executive development and
            succession planning”. The institutional shareholders can urge the
            management to make decisions that benefit shareholders, which can
            protect the rights of shareholders, especially the minority
            stockholders (Fig. 18).
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Chairman of the Board | </span
          ><span style="font-family: Calibri; font-size: 12pt"
            >The chairman of the Board is also CEO in </span
          ><span style="font-family: Calibri; font-size: 12pt">Bloomage</span
          ><span style="font-family: Calibri; font-size: 12pt"> </span
          ><span style="font-family: Calibri; font-size: 12pt">BioTech</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >. The duties of the chairman include organizing the meeting of
            separate investors and the Board, integrating the agenda, engaging
            with shareholders. The chairman and CEO is closely monitored by the
            audit committee to prevent the shareholders' related rights and
            interests from suffering losses due to improper operations.
          </span>
        </p>
        <p style="background-color: #ffffff; margin: 5pt 0pt">
          <span style="color: #1e4c77; font-family: Calibri; font-size: 12pt"
            >Board |</span
          ><span style="color: #1e4c77; font-family: Calibri; font-size: 12pt">
          </span
          ><span style="font-family: Calibri; font-size: 12pt">T</span
          ><span style="font-family: Calibri; font-size: 12pt"
            >he board of directors (15 in all) consist of 3 directors with
            advanced stock raising qualification and rick experience in hog
            production industry and 6 experts with excellency in financing, </span
          ><span style="font-family: Calibri; font-size: 12pt">accounting</span
          ><span style="font-family: Calibri; font-size: 12pt">
            and management field. The directors are evenly distributed across each
            committee. For regular Board meeting, the directors independently meet
            in executive sessions.
          </span>
        </p>
      </div>
      <script
      src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js"
      integrity="sha384-C6RzsynM9kWDrMNeT87bh95OGNyZPhcTNXj1NW7RuBCsyN/o0jlpcV8Qyq46cDfL"
      crossorigin="anonymous"
    ></script>
  </body>
</html>
